Introduction
in vivo, and strategies to increase its effectiveness in cancer treatment without increasing toxicity are urgently required (23).
We demonstrate that over-expression of SphK1 attenuates 67LR-dependent cancer cell death induced by EGCG. Our findings demonstrate that a novel combination of therapeutic agents (EGCG and safingol) shows potent synergistic toxicity in MM cells, without affecting normal cells. The stimulation of ceramide generation by targeting 67LR and SphK1 is a simple and efficient strategy for myeloma-specific chemotherapy. supplemented with 1% FBS, 200 U/mL catalase and 5 U/mL superoxide dismutase (SOD) (Sigma). All cell lines used in the study were obtained.
Cell surface ceramide accumulation
After treatment with EGCG for 3 h, cells were fixed with 2% paraformaldehyde. Cells were washed with PBS and blocked for 1 h in 1% FBS-PBS. Cells were incubated with anti-ceramide antibody (1 mg/mL) (Alexis, Lausen, Switzerland) at 4°C for overnight, followed by incubation with secondary antibody (Alexa Fluor 488) for 30 min. Fluorescent images of cell surface ceramide was analyzed using a fluorescence microscope (Keyence, Tokyo, Japan; Photoshop Software, Adobe Systems, San Jose, CA). (n = 10 per group). A binary solvent gradient with a flow rate of 0.3 mL/min was uses to separate sphingolipids by normal-phase chromatography using an InertSustain NH2 (GL Sciences, Tokyo, Japan 
LC-ESI-MS/MS analysis of ceramides

Western blotting
Immunoblot analysis was performed as previously described (26).
Lipid raft clustering assay
Cells were labeled with 750 nM of DiIC16 labeling solution, then stimulated for varying times with EGCG. After treatment, cells were extracted with 0.5% Triton X-100 on ice for 30 minutes, and then fixed with 2% paraformaldehyde. Fluorescent images of lipid raft staining were analyzed using a fluorescence microscope (Keyence, Tokyo, Japan; Photoshop Software, Adobe Systems, San Jose, CA). (n = 10 per group).
In vitro cell proliferation and apoptosis assay
The number of cells was determined by trypan blue exclusion. Apoptotic MM cells were detected using Annexin V-Alexa Fluor 488 (Life Technologies Corporation, Carlsbad, CA, USA). Cells were mixed with Annexin V-Alexa Fluor 488 and media binding reagent, and a portion of the cell suspension was placed onto a glass slide and immediately observed under a fluorescence microscope, BZ-8100 (Keyence, Tokyo, Japan).
For flow cytometry analysis, the cells were double stained with Annexin V-Alexa Fluor 488 and PI. 
Statistical analysis
Values for the in vitro studies represent the mean ± SD of at least 3 experiments. The significance of difference between the experimental variables was determined by Tukey's test.
Statistical analyses were performed using KyPlot software. 
Results
Activated ASM induces lipid raft disruption
We used an ASM assay to identify a dose-dependent increase in ASM activity following treatment of MM U266 cells with low concentrations of EGCG (Fig. 1A) . Additionally, microscopic (Fig. 1B) and LC-MS/MS (Fig. 1C) analyses revealed a dose-dependent increase in cell surface ceramide levels in U266 cells following EGCG treatment. Displacement of cholesterol from the lipid raft on the plasma membrane occurs after generation of ceramide by ASM (17), and EGCG has been shown to induce disruption of cholesterol-rich lipid rafts in colon cancer cells (27) . Therefore, we next investigated the involvement of ASM in EGCG-induced disruption of lipid raft domains by staining with the lipid-mimetic dialkyl-indocarbocyanine (DilC16) and using a cold Triton X-100 solubility assay ( Fig. 1D and E). Exposure of myeloma U266 cells to C16-ceramide or EGCG (> 10 μM) caused a marked reduction in Triton X-100 resistance of the plasma membrane, indicating that EGCG-induced ceramide generation caused lipid raft disruption.
EGCG induces RTK inhibition via ASM activation
Previous studies have concluded that a cholesterol-rich lipid raft can function as a platform and is associated with RTK activation (18). We used a phospho-RTK array kit to determine the effect of EGCG on RTK activation. Treatment with 10 μM EGCG inhibited fetal bovine serum 
Abnormal over-expression of SphK1 protects cells from EGCG-induced RTK inhibition
Our findings revealed that ASM-generated ceramide contributes to EGCG-induced anti-myeloma activity, suggesting that targeting negative regulators of ceramide could enhance sensitivity to EGCG. EGCG induced ASM activation at low concentrations (1 μM), but did not stimulate ceramide accumulation or disruption of lipid raft formation unless cells were treated with more than 10 μM EGCG. We hypothesized that SphK1 may protect cancer cells from EGCG-induced cell death by down-regulating ceramide levels and up-regulating S1P levels in MM cells (Fig. 3A) . We found that SphK1 levels were markedly increased in MM cells (Fig. 3B) . To determine the impact of SphK1 on the EGCG-induced disruption of lipid rafts, cells were treated with EGCG and safingol, an SphK1 inhibitor. We observed significant disruption of the lipid raft and accumulation of ceramide following combination treatment of U266 cells with both EGCG and safingol ( Fig. 3C and Supplementary Fig.   S3A−B) . Additionally, FBS-induced RTK phosphorylation-including that of IGF-1R-was suppressed following treatment of U266 cells with the EGCG/safingol combination ( Fig. 3D and E).
SphK1 protects cells from 67LR/ASM-dependent apoptotic cell death induced by EGCG
To determine the impact of SphK1 on the anti-MM activity of EGCG, cells were treated with EGCG and safingol. Safingol treatment potently increased EGCG-induced cell death in MM cells isolated from patient samples and all MM cell lines, while having no observable harmful effect on normal PBMCs (Fig. 4A) . This EGCG/safingol-induced specific cell death was attributed to apoptosis ( Fig. S4D ).
SphK2 is another isoform of SphK, therefore, we examined the effects of SphK2 on EGCG-induced cell death. Silencing the expression of SphK2 did not affect the EGCG-induced cell death in U266 myeloma cells ( Supplementary Fig. S5A and B) .
Furthermore, safingol also has an inhibition activity on PKC. Thus, the effect of PKC on EGCG-induced cell death was confirmed by using a potent inhibitor of PKC Ro-318820. Fig. 4D and E) . Moreover, U266 cells were protected from EGCG/safingol-induced anti-MM activity when ASM protein expression was silenced (Fig. 4F ) and when cells were pre-treated with anti-67LR antibodies (Fig. 4G ). This suggests that the 67LR/ASM pathway is central to cell death induced by combined EGCG/safingol treatment. These results demonstrate that targeting over-expressed 67LR and SphK1 in MM cells may be a useful approach for cancer-specific killing.
Combination of EGCG with safingol markedly activates DAPK1 in MM cells
A previous study has reported that ceramide activates death-associated protein kinase 1 (DAPK1), a key mediator of apoptosis (28) . Therefore, we treated U266 cells with or without EGCG and safingol for 96 h to identify the effects of combination EGCG/safingol treatment on DAPK1 activity. Treatment with combination EGCG/safingol reduced p-(Ser308)-DAPK1 levels markedly, leading to increased phosphorylation of the DAPK1 substrate myosin regulatory light chain (MRLC), which induces blebbing in apoptotic cells (Fig. 5A and B) . Supplementary Fig. S7A ) or serum ALT/AST activity ( Supplementary Fig. S7B ). Treatment with EGCG/safingol markedly suppressed tumor growth in mice (Fig. 6A and B) . Moreover, log-rank analysis of Kaplan-Meier survival curves revealed a significant increase in the survival rates of mice treated with combination EGCG/safingol compared with mice exposed to EGCG or safingol alone (Fig. 6C) . Finally, tumors from mice treated with combination EGCG/safingol had reduced levels of p-DAPK1 and p-IGF-1R (Fig. 6D) . These results suggest that co-treatment with safingol increases EGCG-induced anti-tumor activity in mice.
Discussion
The proliferation and survival of MM cells has been linked to the activation of several Hepatotoxicity is an adverse effect of high-dose EGCG (45), and, elevation of the transaminases ALT and AST has been observed in clinical trials (9) . Therefore, the our findings hold great clinical value because safingol first entered clinical trials as an anti-cancer agent and no adverse toxicity was seen for doses up to 20 mg/kg (23,46). Importantly, EGCG and safingol in combination did not increase the serum levels of ALT or AST ( Supplementary   Fig. S4B ). Therefore, combination therapy with safingol may enhance the anti-cancer effects of EGCG.
Interestingly, safingol potentiated EGCG-induced disruption of cholesterol-rich lipid rafts but had no effect on the clustering of ceramide-rich lipid rafts (Supplementary Fig. S2 ). Recent 
